Navigation Links
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Date:9/6/2007

KNOXVILLE, TN--Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) announced that it has obtained approval to begin Phase 2 clinical testing of Provecta for the treatment of Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study is designed to evaluate efficacy of Provecta in a total of 80 subjects.

In the study, Provecta will be injected into up to 20 tumors in each subject. Additional treatment with Provecta may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for 1 year, during which data will be gathered for assessment of objective response rate, progression free survival, quality of life and safety. In addition, CT imaging will be used to monitor changes in any internal (e.g., visceral or brain) metastases. The lead site for the study is the Sydney Melanoma Unit in Australia. Over the next several months the study will expand to include sites in a number of major population centers in Australia as well as several sites in the U.S.

Craig Dees, Ph.D., Chief Executive Officer of Provectus, stated, Building on the results from our Phase 1 study, which looked at safety and objective response upon injection of Provecta into more than 100 metastatic melanoma tumors in 20 subjects, we have put forth an aggressive clinical plan to drive toward approval of the drug for use in this devastating disease. Dees continued, Preliminary analysis of data from Phase 1 shows that Provecta, which has received orphan drug designation in the U.S., was well tolerated with generally mild side effects. Having completed final follow-up for the last of these subjects, we expect to announce summary response data in the near future.


'/>"/>
Contact: Janet Vasquez
janet@investorrelationsgroup.com
212-825-3210
Provectus Pharmaceuticals
Source:Eurekalert

Page: 1

Related medicine news :

1. Risk of heart disease begins in teens
2. Cancer Begins With Epigenetic Changes: Study
3. Learning About Healthy Diet Choices Begins At Schools
4. China Begins Human Trials For HIV/AIDS Drug
5. Administration of Fish Drug for Asthma Patients Begins in Andhra
6. Harvard Begins Controversial Human Stem Cell Cloning Project
7. Writing on the Wall - Lead Poisoning Begins at Home?Paints Could Be Toxic!
8. The Blessing of Good Mental Health Begins with Breast Milk, Says a Study
9. India sounds bird flu alert as migration season begins
10. Keys to Good Health in Old Age Begins in Midlife
11. Cancer Prevention Begins During Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at ... of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and ... , For Valentine’s Day, not only are long-stem roses available, but also other flower ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... Dallas, Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign ... is an app that lets users make and share payments through a smart device. ...
(Date:2/5/2016)... MA (PRWEB) , ... February 05, 2016 , ... ... in tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, ... option with unmatched results. , Developed by Cynosure, the PicoSure has been approved by ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... MOUNTAIN VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... supply management solutions to healthcare systems, today announced results ... 2015.  --> --> ... was $130.3 million, up $5.1 million or 4.1% from ... or 7.2% from the fourth quarter of 2014. Revenue ...
(Date:2/4/2016)... , Feb. 4, 2016 In response to the ... FDA,s Deputy Commissioner for Medical Products and Tobacco, along with ... reassess the agency,s approach to opioid medications. The plan will ... providing patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ...
Breaking Medicine Technology: